Outcomes of the HORNBILL study: A phase I/IIa investigating Sema3A modulator in participants with DMI

media

posted on 2024-11-19, 10:33 authored by Quan Dong Nguyen, Chirag Jhaveri, Maged Habib, Khaled Nassar, Bartlomiej Krawczyk, Michel Wagner, Martin Gliem, Sobha Sivaprasad

<p dir="ltr">The above is a video summary of a clinical trial for diabetic retinopathy with diabetic macular ischemia. The content is not peer-reviewed. Unless otherwise specified, the content on this website has undergone a medical, legal, and regulatory (MLR) review and approval process by Boehringer Ingelheim.</p>

Funding

This study was sponsored by Boehringer Ingelheim

History

Related Materials

1.
URL - Is supplement to https://pmc.ncbi.nlm.nih.gov/articles/PMC9386971/
2.
URL - Is supplement to https://iovs.arvojournals.org/article.aspx?articleid=2788247
3.
URL - Is supplement to https://iovs.arvojournals.org/article.aspx?articleid=2800264&resultClick=1
4.
URL - Is supplement to Study Details | HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia | ClinicalTrials.gov ClinicalTrials.gov

Outcomes of the HORNBILL study: A phase I/IIa investigating Sema3A modulator in participants with DMI

Funding

This study was sponsored by Boehringer Ingelheim

History

Related Materials

Usage metrics

Categories

Keywords

Licence

Exports